Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on GoodRx Holdings yesterday and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Craig Hettenbach has given his Hold rating due to a combination of factors impacting GoodRx Holdings. One significant development is the potential partnership with TrumpRx, which has driven the stock price higher. However, the details of this partnership remain unclear, and its impact on GoodRx’s business model is uncertain at this stage.
Additionally, while the expansion of GoodRx’s partnership with Kroger to offer discounted branded drugs is promising, it is still in the early stages and its long-term benefits are yet to be fully realized. Furthermore, there are concerns about the stability of GoodRx’s prescription transaction business, particularly in light of external challenges such as the RiteAid Chapter 11 filing and ISP headwinds. These uncertainties contribute to the Hold rating, as investors are advised to watch for further developments in these areas.
In another report released on September 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $4.50 price target.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GDRX in relation to earlier this year.